Literature DB >> 17118796

Opsin oligomerization in a heterologous cell system.

Milka Vrecl1, Luka Drinovec, Christian Elling, Anders Heding.   

Abstract

Using bioluminescence resonance energy transfer (BRET) we studied opsin oligomerization in heterologous expression systems and quantitatively assessed its oligomerization state. BRET2 saturation and competition experiments were performed with live COS-7 cells expressing Rluc-and GFP2-tagged receptor constructs. BRET2 saturation curves obtained were hyperbolic, and the calculated oligomerization state (N = 1 for dimers) suggested that opsin (N = 1.34 +/- 0.25) forms higher oligomers. Very high BRET2 values obtained for the opsin homo-dimer pair indicated a large energy transfer efficiency (E) and for cases where E >> 0.1 a modified saturation curve was proposed. The existence of homo-dimer complexes was additionally supported by competition assay results and was also observed in HEK-293 cells. Furthermore, evidence was provided for homo-and hetero-dimerization of family A (beta2-adrenergic) and B (gastric inhibitory polypeptide, GIP) receptors. In summary, these experiments demonstrate homo-and hetero-dimerization for opsin, beta 2-adrenergic, and GIP receptors.

Mesh:

Substances:

Year:  2006        PMID: 17118796     DOI: 10.1080/10799890600932253

Source DB:  PubMed          Journal:  J Recept Signal Transduct Res        ISSN: 1079-9893            Impact factor:   2.092


  11 in total

1.  The Pseudo signal peptide of the corticotropin-releasing factor receptor type 2A prevents receptor oligomerization.

Authors:  Anke Teichmann; Claudia Rutz; Annika Kreuchwig; Gerd Krause; Burkhard Wiesner; Ralf Schülein
Journal:  J Biol Chem       Date:  2012-06-11       Impact factor: 5.157

Review 2.  A day in the life of a G protein-coupled receptor: the contribution to function of G protein-coupled receptor dimerization.

Authors:  G Milligan
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

3.  Evidence for aggregation of protein kinase CK2 in the cell: a novel strategy for studying CK2 holoenzyme interaction by BRET(2).

Authors:  Gerda M Hübner; Jane Nøhr Larsen; Barbara Guerra; Karsten Niefind; Milka Vrecl; Olaf-Georg Issinger
Journal:  Mol Cell Biochem       Date:  2014-08-23       Impact factor: 3.396

4.  Mathematical models for quantitative assessment of bioluminescence resonance energy transfer: application to seven transmembrane receptors oligomerization.

Authors:  Luka Drinovec; Valentina Kubale; Jane Nøhr Larsen; Milka Vrecl
Journal:  Front Endocrinol (Lausanne)       Date:  2012-08-28       Impact factor: 5.555

5.  Regulation of GIP and GLP1 receptor cell surface expression by N-glycosylation and receptor heteromerization.

Authors:  Gina M Whitaker; Francis C Lynn; Christopher H S McIntosh; Eric A Accili
Journal:  PLoS One       Date:  2012-03-07       Impact factor: 3.240

6.  Receptor oligomerization in family B1 of G-protein-coupled receptors: focus on BRET investigations and the link between GPCR oligomerization and binding cooperativity.

Authors:  Sarah Norklit Roed; Anne Orgaard; Rasmus Jorgensen; Pierre De Meyts
Journal:  Front Endocrinol (Lausanne)       Date:  2012-05-07       Impact factor: 5.555

Review 7.  Oligomerization of Family B GPCRs: Exploration in Inter-Family Oligomer Formation.

Authors:  Hans K H Ng; Billy K C Chow
Journal:  Front Endocrinol (Lausanne)       Date:  2015-02-02       Impact factor: 5.555

8.  Demonstration of a direct interaction between β2-adrenergic receptor and insulin receptor by BRET and bioinformatics.

Authors:  Maja Mandić; Luka Drinovec; Sanja Glisic; Nevena Veljkovic; Jane Nøhr; Milka Vrecl
Journal:  PLoS One       Date:  2014-11-17       Impact factor: 3.240

Review 9.  Molecular Pharmacology of the Incretin Receptors.

Authors:  Suleiman Al-Sabah
Journal:  Med Princ Pract       Date:  2015-06-20       Impact factor: 1.927

10.  BRET Biosensor Analysis of Receptor Tyrosine Kinase Functionality.

Authors:  Sana Siddiqui; Wei-Na Cong; Caitlin M Daimon; Bronwen Martin; Stuart Maudsley
Journal:  Front Endocrinol (Lausanne)       Date:  2013-04-09       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.